Neurofibromatosis Treatment Drugs Market to Surpass US$ 21,223.7 Million by 2027

Global Neurofibromatosis Treatment Drugs Market, by Disease Type (Neurofibromatosis 1 (NF1) and Neurofibromatosis 2 (NF2), and Schwannomatosis), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 8,801.0 million in 2020 and is expected to exhibit a CAGR of 13.4% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

Major companies (and more recently medium sized companies) are entering strategic partnerships and collaborations in order to develop novel therapies for neurofibromatosis, which is contributing to growth of the global neurofibromatosis treatment drugs market. For instance, in April 2020, Healx, an AI-powered and patient-inspired tech company specializing in accelerating the discovery and development of rare disease treatments, partnered with Children’s Tumor Foundation (CTF), a U.S. and Europe-based patient group, with an aim to progress new AI-derived therapies for neurofibromatosis (NF).

Global Neurofibromatosis Treatment Drugs Market – Impact of Coronavirus (COVID-19) Pandemic

• The COVID-19 pandemic has drastically affected clinical trials in various therapeutic areas. Many trials have paused enrollment and researchers are facing multiple challenges associated with setting up remote visits, and performing laboratory and other study assessments.
• According to a survey conducted by Medidata Solutions, Inc. (an American technology company, which develops and markets software as a service for clinical trials), on April 23, 2020, 63% of survey respondents reported that they stopped recruiting new patients for ongoing clinical trials and 43% of the respondents have postponed their studies.

Browse 22 Market Data Tables and 24 Figures spread through 166 Pages and in-depth TOC on “Global Neurofibromatosis Treatment Drugs Market, Global Neurofibromatosis Treatment Drugs Market, by Disease Type (Neurofibromatosis 1 (NF1) and Neurofibromatosis 2 (NF2), Schwannomatosis), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the Global Neurofibromatosis Treatment Drugs Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/neurofibromatosis-treatment-drugs-market-4188

The market is expected to gain significant traction during the forecast period due to investments by major players to accelerate research and development of novel therapies for neurofibromatosis. For instance, in June 2020, NFlection Therapeutics, Inc., a biopharma therapeutics developer dedicated to targeting disease pathways to uncover new approaches to fighting rare disease, closed a US$ 20 million Series A financing round with investment from venBio Partners and F-Prime Capital. The company has also announced the initiation of the first clinical trial of its lead product, NFX-179 Gel, a topically applied therapy for the mitigation of cutaneous neurofibromatosis Type-1.

Key Takeaways of the Global Neurofibromatosis Treatment Drugs Market:

• The global neurofibromatosis treatment drugs market is expected to exhibit a CAGR of 13.4% during the forecast period owing to robust product pipeline and increasing approval for the neurofibromatosis treatment drugs. For instance, in April 2020, AstraZeneca Pharmaceuticals received the U.S. Food and Drug Administration’s approval for Koselugo (selumetinib) for treatment of pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1).
• Research collaborations among various research organization has provided an opportunity for key players to initiate the clinical programme targeting neurofibromatosis. For example, The Neurofibromatosis Program at Boston Children’s Hospital is one of the nine sites of a national neurofibromatosis (NF) clinical trials consortium. It has several local research projects, initiated by clinical investigators. Currently, the organization has 11 clinical studies targeting neurofibromatosis.
• Key player operating in the global neurofibromatosis treatment drugs market is AstraZeneca Plc.